— Know what they know.
Not Investment Advice
Also trades as: PROG (NASDAQ) · $vol 6M · BIOR (OTC) · $vol 0M

BIORQ PNK

Biora Therapeutics, Inc.
1W: -50.0% YTD: -100.0%
$0.00
+0.00 (+50.00%)
 
PNK · Healthcare · Biotechnology · $1357 mcap · 3M float · 0.128% daily turnover · Short 34% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000001-0.005
Volume4,187
Avg Volume3,230
Beta5.31
Dividend
Analyst Ratings
1 Buy 2 Hold 1 Sell
Consensus Hold
Company Info
CEOAditya Mohanty
Employees58
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-11
4330 La Jolla Village Drive
San Diego, CA 92122
US
855 293 2639
About Biora Therapeutics, Inc.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Athyrium Opportuniti A-Award 0 $7.57 2024-12-12
Athyrium Opportuniti A-Award 0 $0.76 2024-08-12
Athyrium Opportuniti D-Return 0 $1.56 2024-08-12
Athyrium Opportuniti A-Award 0 $1.56 2024-07-02
Powell Lynne A-Award 12,500 2024-06-05

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms